Curis, Inc. is a biotechnology company that develops and commercializes drug candidates for the treatment of cancer. The company's lead product candidate, CUDC-907, is an oral, small molecule inhibitor of HDAC and PI3K enzymes, which is being developed for the treatment of patients with lymphoma and solid tumors. Curis is also developing CA-4948, a small molecule inhibitor of the IRAK4 kinase, for the treatment of patients with hematologic cancers. The company has collaborations with several pharmaceutical companies, including Aurigene, Genentech, and ImmuNext, to develop and commercialize its drug candidates. Curis was founded in 2000 and is headquartered in Lexington, Massachusetts.